BIBLIOGRAFÍA.

· 1 Abdel Latif A, Messinger-Rapport BJ: Should nursing home residents with atrial fibrillation be anticoagulated?. Cleve Clin J Med 2004 Jan; 71(1): 40-4[Medline].

· 2 AFFIRM Investigators: Baseline characteristics of patients with atrial fibrillation: the AFFIRM Study. Am Heart J 2002 Jun; 143(6): 991-1001[Medline].

· 3 Aronow WS: Management of the older person with atrial fibrillation. J 4Am Geriatr Soc 1999 Jun; 47(6): 740-8[Medline].

· 5 Berry C, Stewart S, Payne EM, et al: Electrical cardioversion for atrial fibrillation: outcomes in "real-life" clinical practice. Int J Cardiol 2001 Nov; 81(1): 29-35[Medline].

· 6 Brass LM, Krumholz HM, Scinto JD, et al: Warfarin use following ischemic stroke among Medicare patients with atrial fibrillation. Arch Intern Med 1998 Oct 26; 158(19): 2093-100[Medline].

· 7 Braunwald E: Heart disease. In: A textbook of Cardiovascular Medicine. 5th ed. Philadelphia: WB Saunders Co; 1997:641-56.

· 8 Crijns HJ, Van Gelder IC, Tijssen JG: Rate control versus electrical cardioversion for persistent atrial fibrillation: a randomized comparison of two treatment strategies concerning mortality and morbidity: the RACE study. Program and abstracts of the American College of Cardiology 51st Annu. Abstract 405-2 2002.

· 9 Farshi R, Kistner D, Sarma JS, et al: Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol 1999 Feb; 33(2): 304-10[Medline].

· 10 Feinberg WM: Anticoagulation for prevention of stroke. Neurology 1998 Sep; 51(3 Suppl 3): S20-2[Medline].

· 11 Fuster V, Ryden LE, Asinger RW, et al: ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology. Circulation 2001 Oct 23; 104(17): 2118-50[Medline][Full Text].

· 12 Hagens VE, Ranchor AV, Van Sonderen E: Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) study. J Am Coll Cardiol 2004 Jan 21; 43(2): 241-7[Medline].

· 14 Halperin JL: Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003 Sep; 146(3): 431-8[Medline].

· 15 Lee KS: Ibutilide, a new compound with potent class III antiarrhythmic activity, activates a slow inward Na+ current in guinea pig ventricular cells. J Pharmacol Exp Ther 1992 Jul; 262(1): 99-108[Medline].

· 16 Mann J: EM Guidemap - Atrial Fibrillation. Available at: http://www.homestead.com/emguidemaps/files/atrialfib.html. Accessed June 3, 2003[Full Text].

· 17 National Heart, Lung, and Blood Institute: Atrial fibrillation: current understandings and research imperatives. The National Heart, Lung, and Blood Institute Working Group on Atrial Fibrillation. J Am Coll Cardiol 1993 Dec; 22(7): 1830-4[Medline].

· 18Pappone C, Rosanio S, Oreto G, et al: Circumferential radiofrequency ablation of pulmonary vein ostia: A new anatomic approach for curing atrial fibrillation. Circulation 2000 Nov 21; 102(21): 2619-28[Medline][Full Text].

· 19 Pritchett EL: Management of atrial fibrillation. N Engl J Med 1992 May 7; 326(19): 1264-71[Medline].

· 20Prystowsky EN, Benson DW Jr, Fuster V, et al: Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation 1996 Mar 15; 93(6): 1262-77[Medline].

· 21 Rathore SS, Berger AK, Weinfurt KP, et al: Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes. Circulation 2000 Mar 7; 101(9): 969-74[Medline].

· 22 Sager PT: New advances in class III antiarrhythmic drug therapy. Curr Opin Cardiol 2000 Jan; 15(1): 41-53[Medline].

· 23 Saxonhouse SJ, Curtis AB: Risks and benefits of rate control versus maintenance of sinus rhythm. Am J Cardiol 2003 Mar 20; 91(6A): 27D-32D[Medline].

· 24 Slavik RS, Tisdale JE, Borzak S: Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence. Prog Cardiovasc Dis 2001 Sep-Oct; 44(2): 121-52[Medline].

· 25 Stollberger C, Chnupa P, Abzieher C, et al: Mortality and rate of stroke or embolism in atrial fibrillation during long-term follow-up in the embolism in left atrial thrombi (ELAT) study. Clin Cardiol 2004 Jan; 27(1): 40-6[Medline].

· 26 Tracy CM: The Modern Management of Minimally Symptomatic Atrial Fibrillation in the Post-AFFIRM Era. Curr Treat Options Cardiovasc Med 2003 Oct; 5(5): 347-354[Medline].

. 27 Wyse DG, AFFIRM Investigators: Survival in patients presenting with atrial fibrillation: the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. Program and abstracts of the American College of Cardiology 51st Annual Meeting; March 17-20, 2002; Atlanta, Ga. Abstract 405-1 2002.